Fennec Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview

Fennec Pharmaceuticals

24/02/2023 19:39

* Fennec Pharmaceuticals Inc  FENC.OQ   FENC.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 27 (estimated). 
    * The Research Triangle Park North Carolina-based  company
is
expected to report revenue of $744.83 thousand, according to the
mean estimate from 6 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Fennec
Pharmaceuticals
Inc is for a loss of 26 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fennec
Pharmaceuticals Inc is $16.5​, above​ its last closing price
of $9.09. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.18       -0.18      -0.31     Missed  -70.6
 Jun. 30 2022  -0.15       -0.14      -0.19     Missed  -39
 Mar. 31 2022  -0.13       -0.14      -0.14     Met     0​
 Dec. 31 2021  1.14        0.75       -0.18     Missed  -124.1
 ​​Sep.        -0.17       -0.17      -0.16     Beat    5.9
 30 2021                                                
 Jun. 30 2021  -0.19       -0.19      -0.15     Beat    20.2​
 Mar. 31 2021  -0.13       -0.13      -0.18     Missed  -38.5
 Dec. 31 2020              -0.19      -0.13     Beat    31.6
 This summary was machine generated February 24 at 19:39 GMT. 
All figures in US dollars  unless otherwise stated